Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Insider David Krempa Sells 10,223 Shares

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) insider David Krempa sold 10,223 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $14.73, for a total transaction of $150,584.79. Following the sale, the insider now owns 612,646 shares of the company's stock, valued at approximately $9,024,275.58. The trade was a 1.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

David Krempa also recently made the following trade(s):

• On Friday, June 13th, David Krempa sold 6,800 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $14.77, for a total value of $100,436.00.
• On Thursday, June 12th, David Krempa sold 16,977 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $14.92, for a total transaction of $253,296.84.

Eton Pharmaceuticals Trading Up 0.7%

NASDAQ ETON traded up $0.09 during trading on Thursday, hitting $13.70. The company had a trading volume of 341,413 shares, compared to its average volume of 227,647. The company's fifty day moving average is $16.63 and its 200-day moving average is $15.03. Eton Pharmaceuticals, Inc. has a one year low of $3.18 and a one year high of $21.48. The company has a current ratio of 1.97, a quick ratio of 1.43 and a debt-to-equity ratio of 1.23. The company has a market cap of $367.43 million, a price-to-earnings ratio of -76.11 and a beta of 1.28.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by ($0.02). The company had revenue of $17.28 million during the quarter, compared to the consensus estimate of $14.33 million. Eton Pharmaceuticals had a negative return on equity of 3.15% and a negative net margin of 9.49%. On average, sell-side analysts predict that Eton Pharmaceuticals, Inc. will post -0.14 earnings per share for the current year.

Analyst Ratings Changes

ETON has been the topic of a number of recent analyst reports. B. Riley reissued a "buy" rating and issued a $26.00 price target (up previously from $24.00) on shares of Eton Pharmaceuticals in a report on Friday, May 16th. HC Wainwright reissued a "buy" rating and issued a $35.00 target price (up from $33.00) on shares of Eton Pharmaceuticals in a research note on Thursday, May 29th. Finally, Craig Hallum upped their price target on Eton Pharmaceuticals from $26.00 to $28.00 and gave the company a "buy" rating in a research report on Wednesday, May 14th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. AlphaQuest LLC purchased a new position in Eton Pharmaceuticals during the first quarter valued at $53,000. Tower Research Capital LLC TRC bought a new position in shares of Eton Pharmaceuticals in the 4th quarter worth about $86,000. Quantbot Technologies LP purchased a new position in Eton Pharmaceuticals during the 1st quarter valued at about $101,000. Jefferies Financial Group Inc. bought a new stake in Eton Pharmaceuticals during the fourth quarter worth about $133,000. Finally, Point72 Asia Singapore Pte. Ltd. boosted its stake in Eton Pharmaceuticals by 18.3% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 10,561 shares of the company's stock worth $141,000 after acquiring an additional 1,634 shares in the last quarter. Hedge funds and other institutional investors own 27.86% of the company's stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.